These spatial biomarkers offer unique insight into whether PD-L1+ cells are enriched in the vicinity of functional targets (in which case inhibition of the PD-1/PD-L1 axis is thought to be more likely to amplify anti-tumour immunity) (60) or randomly distributed throughout the TME, and can only be measured through multiplexed imaging. The gene discussed is CD274; the disease is neoplasm.